Phospho-RSK2 (Tyr529) Antibody #9324
- WB
Inquiry Info. # 9324
Please see our recommended alternatives.
Product Specifications
| REACTIVITY | H Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 90 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Phosphorylation of RSK2 on Tyr529 was identified at Cell Signaling Technology (CST) using PhosphoScan®, our LC-MS/MS platform for phosphorylation site discovery. This study identifies RSK2 as a key substrate of FGFR3 in human t(4;14)-positive multiple myeloma (MM) cells. Constitutively active FGFR3 directly phosphorylates RSK2 on Tyr529, which primes RSK2 for activation by ERK1/2 (4). Mutations in the RSK2 gene are associated with Coffin-Lowry syndrome (CLS), an X-linked disorder characterized by mental retardation and the presence of characteristic facial anomalies (5).
Alternate Names
90 kDa ribosomal protein S6 kinase 3; CLS; epididymis secretory sperm binding protein; HU-3; Insulin-stimulated protein kinase 1; ISPK-1; ISPK1; KS6A3; MAP kinase-activated protein kinase 1b; MAPK-activated protein kinase 1b; MAPKAP kinase 1b; MAPKAPK-1b; MAPKAPK1B; mental retardation, X-linked 19; MRX19; p90-RSK 3; p90-RSK2; p90RSK3; pp90RSK2; ribosomal protein S6 kinase A3; Ribosomal protein S6 kinase alpha-3; ribosomal protein S6 kinase, 90kDa, polypeptide 3; Ribosomal S6 kinase 2; RPS6KA3; RSK; RSK-2; RSK2; S6K-alpha-3; S6K-alpha3
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.